oral menin-MLL1 inhibitor

Ph. I/II candidate in leukemia

from HTS and SBDD

Mixed Lineage Leukemia 1 (MLL1)

Kura Oncology, San Diego, CA

Ziftomenib chemical structure oral menin-MLL1 inhibitor - Kura Oncology, San Diego, CA

Context. Ziftomenib (KO-539; MD Anderson) is an oral menin inhibitor being developed for mixed-lineage leukemia 1 (MLL1)-rearranged or NPM1-mutated acute myeloid leukemia (AML). Although a tumor suppressor in endocrine…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: